# Semma Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/semma-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.semma-tx.com
- Total disclosed funding: $129M
- Latest round: Series B (Nov 30, 2017)
- Investors on record: 12

## About

Semma Therapeutics, Inc. is a biotechnology firm focused on developing cell therapies for diabetes treatment, aiming to transform insulin-dependent patients' lives through innovative solutions.Founded in 2014 and headquartered in Cambridge, US, Semma Therapeutics, Inc. specializes in developing cell-based therapies for diabetes. The company was acquired by Vertex Pharmaceuticals Incorporated in a deal valued at USD 950 mn, which closed in the fourth quarter of 2019. The acquisition aimed to leverage Semma's expertise in cell therapy to enhance Vertex's portfolio. Prior to this acquisition, Semma Therapeutics had successfully completed five deals since its inception, with the most recent deal occurring on September 3, 2019.Semma Therapeutics focuses on developing innovative cell therapies aimed at treating diabetes, particularly type 1 diabetes. The company is pioneering the use of encapsulated insulin-producing cells to restore natural insulin production in patients, thus potentially reducing their dependency on external insulin sources. Through these advancements, Semma aims to improve patient health outcomes and quality of life, supported by comprehensive patient programs.As a biotechnology company, Semma Therapeutics generates revenue through strategic partnerships and potential future product sales once its therapies are brought to market. While specific revenue figures are not disclosed, their business model is based on collaborations with larger pharmaceutical companies and healthcare systems.Following its acquisition by Vertex Pharmaceuticals, Semma Therapeutics is poised for significant growth through the development of its cell-based therapies for diabetes. The recent acquisition funding of USD 950 mn will be utilized to further research and development efforts, aiming to accelerate the commercialization of its innovative technologies. Vertex intends to expand Semma's reach into new markets, focusing on North America and Europe, with plans to advance clinical trials in these regions in the coming years.

## Funding rounds

- Series B, Nov 30, 2017, $114M — ARCH Venture Partners, Novartis Venture Fund, Eight Roads Ventures, F-Prime Capital, MPM BioImpact, Medtronic Ventures, Shanghai Jianyi Private Equity Fund Management, Wu Capital, 6 Dimensions Capital, Cowen Investment Management, JDRF T1D Fund, ORI Capital
- Series A, Mar 19, 2015, $15M — ARCH Venture Partners, F-Prime Capital, MPM BioImpact, Medtronic Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Medtronic Ventures (https://capitalatlas.ai/funds/medtronic-ventures) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- Wu Capital — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- Cowen Investment Management — Series B
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series B
- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series B